LUMAKRAS (Sotorasib)

Access LUMAKRAS (Sotorasib) in India

LUMAKRAS (Sotorasib) has been approved in countries like the U.S. and Europe but is not yet available for commercial sale in India. However, it is accessible through the Named Patient Program (NPP) for eligible patients.

MitoGENE helps Indian patients access LUMAKRAS (Sotorasib) legally and safely under their doctor’s supervision. We handle the documentation, regulatory approvals, and logistics to ensure compliance with Indian regulations.

If you or your loved one may benefit from LUMAKRAS (Sotorasib), MitoGENE is here to support your journey to access this treatment.

Product Description:

LUMAKRAS (Sotorasib) is a prescription medication indicated for the treatment of adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have previously received at least one systemic therapy.

*In the European Union, sotorasib is approved by the EMA under the brand name Lumykras.

Disease Indications: Lung Cancer

Manufacturer: Amgen GmbH (DE)

Shipping: Room Temperature Shipping. This medication is shipped using standard delivery methods, ensuring it remains within a controlled room temperature range of 15°C to 25°C throughout transit.

This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.

Note: We can assist only if the medicine is unavailable in your country.”

MitoGENE helps Indian patients access Lumakras (sotorasib) legally and safely under their doctor’s supervision.

Available Dosage Form& Package

  • 240 Tablets of 120 mg

Medicine Approved by:

  • European Medical Agency (EMA)
  • Food and Drug Administration (FDA)
  • Medicines & Healthcare products Regulatory Agency (MHRA)

What is Lumakras (sotorasib) used for?

Lumakras is a prescription drug for adults with non-small cell lung cancer (NSCLC) that:

  • Is locally advanced or metastatic
  • Has a KRAS G12C mutation
  • Has progressed after at least one prior systemic treatment

Each tablet contains 120 mg of sotorasib.

How does it work?

Around 13% of NSCLC cases have a KRAS G12C mutation, which leads to abnormal cell growth. Lumakras blocks this mutated KRAS protein, helping to slow or stop tumor growth.

It’s an oral targeted therapy—not chemotherapy, immunotherapy, or a tyrosine kinase inhibitor.ble. However, eligible patients may be able to access it through the Named Patient Program, a legal pathway for importing global cancer medicines under the supervision of their treating oncologist.

How to take it

  • Dose: 960 mg (eight 120 mg tablets) once daily
  • Take with or without food at the same time each day
  • Continue until disease worsens or side effects are not manageable

Note:

  • If vomiting occurs, don’t retake. Resume next dose as scheduled.
  • Avoid with acid reducers like PPIs or H2 blockers. Antacids should be taken 4 hours before or 10 hours after.

Side effects

Common:

  • Diarrhea, fatigue, nausea
  • Muscle/bone pain
  • Cough, liver issues
  • Abnormal lab tests

Serious:

  • Liver and lung problems

Pregnancy/Breastfeeding:
Unknown risks. Do not breastfeed during treatment and for 1 week after the last dose.

References

1. Full prescribing information [FDA]: Lumakras (sotorasib) [PDF]
Amgen, May 2021

2. KRAS G12C inhibition
Amgen, cited May 2021

3. Sotorasib (AMG 510) Precision Cancer Medicine Targets KRAS NSCLC
Cancer Connect, Feb 2021

4. FDA Approves LUMAKRAS™ (Sotorasib), The First And Only Targeted Treatment For Patients With KRAS G12C-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Amgen, May 2021

5. Amgen’s high-profile cancer med Lumakras set for rollout in England thanks to NHS access deal
Fiercepharma.com, Sep 2021

Disclaimer: ZELBORAF (vemurafenib) is not approved for commercial sale in India. Access is provided strictly for personal use under physician supervision in accordance with Indian regulatory guidelines through the Named Patient Program (NPP). MitoGENE does not market, advertise, or sell unapproved drugs. All content is for informational purposes and not a substitute for professional medical advice.

How to Access LUMAKRAS (Sotorasib) in India in 4 Simple Steps with MitoGENE via the Named Patient Program (NPP)?

If LUMAKRAS (Sotorasib) is not yet approved or commercially available in India, MitoGENE can assist you in accessing it legally through the Named Patient Program (NPP). Here’s how the process works:

Process to Import LUMAKRAS (Sotorasib) in India legally through Named Patient Program approved by CDSCO
Named Patient Program and process to Import unapproved medicines legally in India, Get Lates Cancer Medicines FDA approved and EMA approved in India Leagally
Named Patient Program and process to Import unapproved medicines legally in India, Get Lates Cancer Medicines FDA approved and EMA approved in India Leagally
Named Patient Program and process to Import unapproved medicines legally in India, Get Lates Cancer Medicines FDA approved and EMA approved in India Leagally

    Upload Prescription

    Upload Patient Consent Form

    Patient Consent Form
    Download

    Please download and complete this form, including your signature, and attach it to the request form or email it to info@mitogene.org along with the patient details.